surmount-1 trial tirzepatide weight loss nondiabetic SURMOUNT 1 // Three-Year Obesty & Diabetes Prevention Outcomes

SURMOUNT-1 Trial

24.89

★★★★☆4.8 (126)

SURMOUNT-1 (NEJM 2022) tested tirzepatide — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants

27.78

★★★★★4.9 (98)

Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity

28.32

★★★★★5.0 (157)

In the SURMOUNT-4 trial, 82.5% of adults with obesity regained ≥25% of initial weight lost within one year of tirzepatide withdrawal; most showed reversal of cardiometabolic improvements. https://bit.ly/4rBMZgh

26.54

★★★★★4.7 (84)

For the first time, tirzepatide and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at maximum tolerated dose. The

26.16

★★★★★4.9 (203)

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

28.23

★★★★★5.0 (176)

SURMOUNT‐1 study design. This is a phase 3, multicenter, randomized,

20.94

★★★★★4.8 (132)